ENHERTU (fam-trastuzumab deruxtecan) represents a paradigmatic advancement in cancer medicine, fundamentally altering therapeutic landscapes for HER2-positive malignancies worldwide. This cutting-edge antibody-drug conjugate, developed through collaborative innovation between Daiichi Sankyo and AstraZeneca, has achieved unprecedented regulatory success with approvals encompassing breast cancer,...